相关实验视频

Updated: Sep 8, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

在没有反应后治疗牛皮关节炎的生物序列:叙述性审查

Nicole D Boswell¹, Alexa Ries¹, Kenneth B Gordon¹

¹Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA.

Dermatology and therapy

|July 18, 2025

概括

牛皮关节炎的治疗正在发展. 使用17-interleukin和23-interleukin抑制剂的新生物序列为患有牛皮关节炎的患者提供了替代方案,特别是当瘤亡因子抑制剂失败时.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
皮肤病学皮肤病学

背景情况:

牛皮关节炎 (PsA) 是一种复杂,异质的自身免疫性疾病.
瘤坏死因子 (TNF) 抑制剂一直是PsA的传统一线生物疗法.
新出现的数据支持互白素 (IL) - 17和IL - 23抑制剂的疗效,特别是在TNF抑制剂耐药病例中.

研究的目的:

提出一种生物测序策略,用于牛皮关节炎 (PsA).
将疾病严重程度,并发性牛皮 (PsO) 和轴性疾病纳入治疗选择.
引导临床医生优化生物疗法,并为PsA患者保留未来的选择.

主要方法:

一个拟议的生物测序框架被开发出来.
该框架整合了临床试验数据和专家意见.
考虑的是PsA疾病的严重程度和同时发生的PsO和轴性疾病.

主要成果:

拟议的序列旨在优化PsA患者的生物选择.
它解决了对先前的生物疗法没有反应的场景.
它考虑了同时发生的牛皮和轴性疾病对治疗选择的影响.

结论:

在PsA的生物测序需要一个细微的方法,考虑到疾病的复杂性.
IL-17和IL-23抑制剂代表了PsA的有价值的治疗选择,特别是在TNF抑制剂失效后.
需要对IL-17和IL-23抑制剂的顺序使用进行进一步的研究,特别是在PSA的轴性疾病中.

关键词:

生物制剂生物制剂生物制剂生物药物和牛皮生物药物和牛皮关节炎没有回应,没有回应.牛皮是一种病.

更多相关视频

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...